The Carlyle Group [NASDAQ: CG] disclosed that it has decided to purchase Unchained Labs for $435 million. Unchained Labs has gained recognition as the fast-growing life sciences tool firm. Since its inception in 2015, its endeavoring to solve the problems of biologics and gene therapy researchers.
The acquisition by The Carlyle Group is a milestone deal for the firm. This deal is beneficial for the firm as it is in start to scratch the surface of biologics and gene therapy chance. The competent team, strong vision, deep know-how, and capital of Carlyle will speed up the organic and inorganic growth of Unchained Labs.
On the other hand, The Carlyle Group has prolonged its commitment to healthcare. The firm has invested more than $16 billion in equity in healthcare since its foundation. Additionally, equity capital for the purchase came from Carlyle Partners VII. An $18.5 billion capital makes majority and strategic minority financings originally in the U.S. in targeted businesses, including healthcare.
Furthermore, it has been disclosed that Carlyle has purchased Lab in partnership with its management team, Novo, Canaan Partners, and TPG Biotech. The deal closure is dependent on certain regulatory conditions. Moreover, it is anticipated that the deal will be executed in Q2 2021.